M-M-R II Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of national immunization schedules, declining incidence of measles mumps and rubella, widespread public health vaccination campaigns, availability of cold-chain vaccine logistics, increased pediatric healthcare access.

The growth in the forecast period can be attributed to increasing focus on outbreak prevention, rising investments in vaccine manufacturing capacity, expansion of adult immunization programs, growing emphasis on global vaccination equity, increasing adoption of combination vaccine platforms. Major trends in the forecast period include increasing emphasis on routine childhood immunization programs, rising demand for combination vaccines, expansion of public immunization coverage, enhanced focus on vaccine safety and efficacy, growing use of pre-filled syringe formats.

The increasing incidence of measles, mumps, and rubella is expected to drive the growth of the M-M-R II market in the future. Measles, mumps, and rubella are highly contagious viral infections that can lead to serious health complications, such as fever, rash, swelling, and in severe cases, neurological damage or congenital disabilities if rubella is contracted during pregnancy. The rise in cases of these diseases is primarily due to lower vaccination rates, gaps in immunization coverage, and vaccine hesitancy among certain populations. The M-M-R II vaccine provides protection against these diseases by stimulating the immune system to produce antibodies that help prevent infection and reduce the risk of severe health problems. For example, in May 2024, the UK Health Security Agency reported that 51 laboratory-confirmed cases of mumps were recorded in England between January and March 2023, an increase from 32 cases in the previous quarter and 10 cases from July to September 2022. During the same period, 31 laboratory-confirmed measles cases were reported, up from just 7 cases in the prior quarter. As a result, the growing number of measles, mumps, and rubella cases is contributing to the expansion of the M-M-R II market.

The growing success rate of vaccination programs is expected to further drive the M-M-R II market. Vaccination programs are organized initiatives by governments or health organizations to administer vaccines to individuals or populations in order to prevent the spread of infectious diseases. The success of these programs is attributed to factors such as widespread public awareness, efficient vaccine distribution networks, government backing, and the availability of safe and effective vaccines. These programs are essential in promoting the M-M-R II vaccine, which helps prevent measles, mumps, and rubella, reducing the incidence of these diseases and improving public health. For instance, in June 2023, the UK Health Security Agency reported that, under the school-aged vaccination program, 3,502,566 children (from Reception to Year 9) were vaccinated in the 2022-2023 period, compared to 3,615,536 children in the same age range in 2021-2022. As a result, the increasing success rate of vaccination programs is contributing to the growth of the M-M-R II market.

A key trend in the M-M-R II market is the development of innovative therapies, such as live attenuated vaccines, aimed at improving immunization efficacy and expanding protection against measles, mumps, and rubella. A live attenuated vaccine contains a weakened version of the pathogen, which is still capable of triggering an immune response without causing illness. For example, in March 2023, Merck & Co. Inc., a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for the intramuscular administration of the M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live). This vaccine is used to prevent measles, mumps, and rubella in individuals aged 12 months and older. It can be administered either intramuscularly or subcutaneously, with the first dose recommended at 12 to 15 months of age and a second dose at 4 to 6 years.

Major companies operating in the m-m-r ii market are Merck & Co. Inc.

North America was the largest region in the M-M-R II market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the m-m-r ii market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the m-m-r ii market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the m-m-r ii market by increasing costs of imported vaccine raw materials, vial components, syringe systems, and cold-chain storage equipment essential for vaccine production and distribution. Public health agencies and vaccine manufacturers in North America and Europe are most affected due to cross-border sourcing of biologic inputs, while developing regions face higher procurement costs for immunization programs. These tariffs may increase program-level vaccination expenses and strain public health budgets. At the same time, they are encouraging domestic vaccine manufacturing, regional fill-finish capabilities, and investments in localized cold-chain infrastructure to strengthen supply security.

The m-m-r ii market research report is one of a series of new reports that provides m-m-r ii market statistics, including m-m-r ii industry global market size, regional shares, competitors with a m-m-r ii market share, detailed m-m-r ii market segments, market trends and opportunities, and any further data you may need to thrive in the m-m-r ii industry. This m-m-r ii market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

M-M-R II is a combination vaccine that provides protection against three viral infections: measles, mumps, and rubella. It contains live, attenuated (weakened) forms of these viruses, which stimulate the immune system to recognize and combat these infections without causing the diseases themselves. M-M-R II is typically administered as a two-dose series, with the first dose given at 12 to 15 months of age and the second dose at 4 to 6 years, as part of routine childhood immunization programs.

The main indications for M-M-R II are measles, mumps, and rubella. Measles is a highly contagious viral infection characterized by fever, cough, runny nose, and a distinctive red, blotchy skin rash. The vaccine is available in live attenuated formulations and pre-filled syringes. It is distributed through various channels, including hospitals, pediatric clinics, public health agencies, and retail pharmacies. M-M-R II is used by a broad range of end users, including infants, children, adults, and patients receiving immunization services.

The M-M-R II market consists of sales of single antigen vaccines, proquad vaccine, priorix vaccine, and ruvax vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.